CagriSema Blend Testing & Verification (Cagrilintide · Semaglutide)
Independent, third-party analysis of CagriSema blend vials by RP-HPLC-UV — an amylin analog and a GLP-1 analog in one vial, each resolved and reported separately on one certificate.
What CagriSema is
CagriSema is a trade name for one vial carrying Cagrilintide and Semaglutide together. The grey-market product borrows the name from a clinical combination but the vials we receive carry their own labels — most commonly an 8/4 mg split — which is why the split on the order form is editable and the certificate reports what your label declares. Both actives are long, lipidated, synthetically demanding peptides that resolve as separate peaks under our method and are each quantified against their own certified reference standard; a single purity figure for the vial would tell you nothing about either. Our certificate leads with the name on your label and prints the two actives beneath it, each with its own results row.
Why get your CagriSema independently tested
- A borrowed name on a non-standard split: the label on a grey-market CagriSema vial can declare almost any ratio. Each active gets its own identity, purity, and content line, judged against the split you declare, so the certificate speaks to your vial rather than to the name.
- Substitution inside the GLP family: a cheaper lipidated peptide can stand in for Semaglutide, and Cagrilintide is easily replaced by nothing at all. Identity against separate standards, with the neighbouring GLP-class standards on hand, confirms which compounds are present.
- Underfilling on expensive actives: small claims on costly peptides are where fill error hurts most. The per-active net-peptide assay reports each compound's measured milligrams against its declared share.
- Synthesis-related impurities on long lipidated sequences: truncations, deletions, and incomplete side-chain conjugation show as additional peaks near each parent. Per-active purity as area percent reports how clean each one is.
What we measure on CagriSema
A CagriSema certificate reports, for EACH of the two actives, by reversed-phase HPLC with diode-array detection at 214 nm: identity (retention-time and UV-spectral match against that compound's own certified reference standard), chromatographic purity as area percent, content in milligrams per vial, and retention time — one vial, one certificate, one verification code, two fully reported compounds. Appearance and optional pH are reported at the vial level.
Every result is issued as a certificate of analysis you — or anyone you forward it to — can verify cryptographically. Reporting identity, purity, and milligram content is the point: a vial can be pure and still underfilled, so we report all three. More on purity vs. net-peptide content and how to read a peptide COA.
Our scope — stated plainly
Testing is RP-HPLC-UV against certified reference standards for each declared active — not mass spectrometry. The certificate reports the actives declared on your label; it does not de-novo identify unlabelled compounds. KMD Analytical is an independent laboratory; we do not perform sterility, endotoxin, heavy-metal, or residual-solvent testing, and a KMD certificate says nothing about equivalence to any clinical product.
KMD is an independent RP-HPLC-UV lab. We do not run LC-MS / mass-spec, sterility, endotoxin, or heavy-metal testing. If your job needs a capability we don't have, we'll say so.
CagriSema testing — FAQ
Is this the same as the clinical CagriSema?
No. CagriSema on the research market is a name applied to vials of Cagrilintide and Semaglutide in whatever split the vendor chose. We test what is in your vial against the split on your label; the certificate makes no claim about equivalence to any pharmaceutical product.
Do Cagrilintide and Semaglutide separate on HPLC?
Yes. They are different sequences with different lipid attachments and elute at distinct retention times under our method; each is identified against its own reference standard and quantified on its own calibration.
My split isn't 8/4 — can you still test it?
Yes. The 8/4 split is only the most common label; the blend preset pre-fills it when you order and you edit it to match your vial. Each active is verified against whatever your label declares.
Do I get one certificate or two?
One. A blend vial produces a single certificate with one verification code, on which each declared active has its own identity, purity, content, and retention-time row.
What's in this blend, and related tests
Cagrilintide · Semaglutide · Reta/Cagri · Retatrutide · Tesamorelin · see the full panel.
CagriSema is a blend, so it prices per active — the tier rate ($150/vial, $125 at 5+, $100 at 10+) plus 50% for each additional active, since every compound in the vial is resolved and reported separately. Rush results in 4 business days. Start an order or see the full rate card.